INTRODUCTION
Multiple myeloma has extremely heterogeneous outcomes. Among many prognostic factors utilized in myeloma, translocation t(4;14)(p16. What is also unknown in myeloma is the presence of biological homology shared between high-risk and non-high-risk subgroups. This question comes within the context of the recent advancement of genetic sequencing, which identified diverse spectrum of disease biology that, at times, redefined conventional risk stratification and management. For instance, "BRCA-ness" was identified in up to 14% of non-small cell lung cancer and 15% of head and neck cancer patients due to epigenetic inactivation of We hypothesize there is an overlap of disease biology between the established high-risk myeloma and its non-high-risk counterpart. Specifically, the same genes involved in the pathogenesis and adverse outcomes of MMSET myeloma (6) could also be relevant to a subset of Non-MMSET patients with poor clinical outcomes (hereby refer to "MMSET-like myeloma"). To characterize genes and molecular pathways influencing survival across different myeloma subtypes, we assessed expression levels of 54,675 genes in 1,188 newly diagnosed multiple myeloma patients.
Among 71 genes significantly altered in MMSET myeloma, 10 genes most strongly associated with survival were selected and combined into a GEP risk score. Patients who did not have detectable MMSET but were at the top quartile of the 10-gene risk score were categorized as MMSET-like myeloma. Five-year survivals were similar between patients with MMSET myeloma and MMSET-like myeloma. Pathway analysis identified MYC and TP53 transcriptional regulators as lead candidates targeted by the observed genes within the risk score. Our findings suggest there is a homology of aggressive disease biology and clinical outcomes shared between MMSET myeloma and a subset of non-MMSET myeloma.
METHODS

Study design
From the NCBI Gene Expression Omnibus (GEO), we downloaded unprocessed CEL files from the following datasets: Total Therapy (TT) 2 (N=345, accession number GSE2658, NCT00083551); TT 3 (N=214, accession number GSE2658, NCT00081939); HOVON65/GMMG-HD4, (N=320, accession number GSE19784, ISRCTN64455289); Myeloma IX (N=247, accession number GSE15695, ISRCTN68454111); and Multiple Myeloma Reference Collection (MMRC) (N=288, accession number GSE26760). The sample size of each data set was determined after excluding 8 profiles (accession number GSE19784) that were normal plasma cells and 16 patients (accession number GSE26760) who were smoldering myeloma (n=11), MGUS (n=2), or plasma cell leukemia (n=3). Anonymized patient characteristics of TT trials were obtained from GEO and were identified with the same accession numbers. Anonymized patient characteristics of Myeloma IX and HOVON65/GMMG-HD4 trials were obtained through personal correspondence with Mark van Duin and Ping Wu, respectively. Anonymized patient characteristics of MMRC were obtained from Multiple Myeloma Genome Portal.
(12) Selected characteristics of patients from the five studies are shown in Table 1 .
All gene-expression data were derived from CD138+ purified plasma cells of newly diagnosed myeloma patients, which were hybridized to Affymetrix Human Genome U133 Plus 2.0 cDNA microarray (Santa Clara, CA). All raw CEL files were processed using the justMAS function in the R statistical programming language, and gene-expression levels were log2 transformed. The final dataset included GEPs of 1,188 myeloma patients with complete data for age, sex, beta-2 microglobulin, and probe, study-specific linear regression coefficients for MMSET myeloma were then combined across studies using a random effects meta-analysis. (15) Prior to finalizing the probes that were significantly associated with MMSET myeloma, all 700 gene probes used in the Arkansas model (13) were removed. We performed a random effects meta-analysis after Bonferroni correction for multiple testing (p<0.05/54,675=9.14x10 -7 ).
The absolute value of the random effects slope parameter for MMSET myeloma was 2 or greater, indicating MMSET myeloma had 2-fold or greater changes in log expression of a given gene.
Identification of probes associated with survival in Non-MMSET patients
To identify probes relevant to survival of non-MMSET patients, results from the aforementioned meta-analysis were analyzed by a stepwise variable selection (proc by the start of treatment until death or censoring. Censoring occurred when a subject reached 5 years or was lost to follow up. For the initial selection of probes, we included probes that passed Bonferroni correction for multiple testing, and those showed log 2 or greater changes of expression. For each probe, a minimal p<0.1 in a marginal Cox proportional hazards model was set for initial inclusion, and a criteria of p<0.05 was set to retain a probe in the model. All models were adjusted for age, sex, ISS stage (14) and treatment. (16) (17) (18) The risk score was calculated based on the adjusted Cox regression model (Appendix 1).
Validation
To assess the unbiased association of the risk score and survival, we conducted a 5-fold cross-validation. (18) Briefly, the original dataset was divided into five equal parts, with equal numbers of patients from individual studies in each part. Four of the five parts were used to develop a gene signature following the aforementioned procedures (training set). The remaining fifth part was used to compute the association of the risk score and survival using Cox regression models (test set). Validation was performed five times with each part serving as a test set once. Risk scores from five test sets were median-centered and combined to form an independently scored measure of risk.
Sensitivity analysis
To assess stability of our results, we conducted three separate sensitivity analyses (Supplemental Tables 1 and 2 ). First, we used survival outcomes throughout the full follow-up time of up to 98 months instead of censoring at 60 months. Second, we excluded patients who were treated with proteasome inhibitor-based regimens, such as VTD-PACE and PAD, from the analysis. Third, patients on Myeloma IX trial were coded separately if they encountered death or censoring before the second randomization for thalidomide maintenance. In all three sensitivity analyses, the main results remained unchanged.
Pathway analysis
To determine biological functions of the identified gene probes, pathway analysis was performed using Ingenuity Pathway Analysis software package and the molecular signaling database from the Broad Institute (MsigDB). (19) Gene networks were constructed using the upstream regulator analysis to identify transcription factors with the most interactions with selected genes (Figure 1 ).
RESULTS
Among 1,032 myeloma patients included in this study, 139 (13.4%) had MMSET myeloma defined by GEP (Table 1) . (13) In MMSET myeloma, the median age was 59 years (range 24-89), and 68% were males. Distributions of ISS stage I, II, and III were 48%, 30% and 22%, respectively. Similar to prior reports (6), MMSET myeloma was associated with a higher mortality after adjusting for age, sex, ISS stage and treatment (hazard ratio (HR) =1.7, p<0.001).
To determine if the same genes involved in MMSET myeloma were also relevant to survival of Non-MMSET myeloma patients, we took the following analytical approach:
First, as described in the Methods, we obtained GEPs of 1,188 newly diagnosed myeloma patients and defined 71 gene probes correlated with MMSET myeloma (Supplemental Table 3 ). From these probes, we further identified those associated with Table 3 ). Genes highly correlated with MMSET myeloma included cyclin D1 (CCND1), cyclin D2 (CCND2), a transcription factor Kruppel-like factor 4 (KLF4), ubiquitin carboxyl-terminal esterase L1 (UCHL1), and alpha-2-glycoprotein (AZGP1) (Supplemental Table 3 ).
Probes enriched in MMSET myeloma, Non-MMSET myeloma, and survival
From the identified 71 gene probes, 10 genes were strongly associated with 5-year survival of Non-MMSET patients (Table 2) . AZGP1 and CCND1 were most significantly associated with survival (probe-specific HRs: 0.89-0.91 for CCND1 and 1.07-1.14 for AZGP1, p<0.001). To define risk scores relevant to survival of non-MMSET myeloma patients, a multivariable Cox proportional hazards model was applied to the 10 genes.
Risk score groups of the first quartile (low-risk) and the fourth quartile (high-risk) were compared within Non-MMSET patients in cross-validation. High-risk Non-MMSET patients (here by referred as "MMSET-like myeloma") had a similarly increased risk of mortality (HR=2.0, 95% confidence interval (CI) 1.5-2.8, p<0.001) comparable to MMSET patients (HR=2.3, 95% CI 1.6-3.3, p<0.001).
Research. 
Pathway analysis
To characterize genes and molecular pathways influencing survival across different myeloma subtypes, we conducted analysis of the 10 genes associated with 5-year survival in MMSET-like myeloma by using IPA (Ingenuity® Systems). Pathway analysis identified MYC and TP53 transcriptional regulators as lead candidates for the observed gene expression changes within the gene signature risk score (Figure 1) . TP53 was identified as a transcriptional regulator of four genes (CCND1, PTP4A3, MYBL1, and ROBO1) (p=1.9x10 
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